Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine

被引:2
|
作者
Radwan, Asma [1 ]
Shraim, Naser [1 ]
Elaraj, Josephean [1 ]
Hamad, Anwar [1 ]
Fatayer, Dana [1 ]
Jarar, Bayan [1 ]
Johar, Ayoub [1 ]
Zriqah, Areen [1 ]
机构
[1] Najah Natl Univ, Coll Med & Hlth Sci, Dept Pharm, POB 7, Nablus, Palestine
关键词
Osteoporosis; Alendronate; Dosing instructions; Compliance; Palestine; BISPHOSPHONATES; ADHERENCE; PERSISTENCE; CARE;
D O I
10.1186/s12905-022-01690-5
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Postmenopausal women compliance to alendronate therapy is suboptimal due to the complex dosing requirements. The poor compliance may increase their potential of fractures and the prevalence of side effects. In this study, the compliance of osteoporotic women on bisphosphonate therapy to the complex dosing instructions and their knowledge of alendronate-interactions were assessed. Methods This is a cross-sectional study, using self-administered questionnaire involving 224 osteoporotic women on alendronate therapy, who visited the orthopedic clinics and community pharmacies in the West Bank. Data was collected using a validated questionnaire consisting of 4 sections and analyzed by descriptive statistics. Moreover, associations between patient's socio-demographic characteristics and the extent of compliance and knowledge of alendronate interactions are established in this study. Results A total of 300 questionnaires were distributed and 224 were completed. The median compliance score to alendronate dosing instructions was 5 out of a possible maximum 7, and the median knowledge score about alendronate interactions was 7 out of a possible maximum 14. Factors found to affect either or both the knowledge and compliance to alendronate dosing instructions were, residency, and the source of instructions. Conclusion This study identified the importance of compliance and knowledge gaps among postmenopausal women treated with alendronate. Therefore, appropriate knowledge about the importance of proper compliance to dosing instructions and avoidance of interactions is of a great benefit for maximizing clinical effectiveness, lowering fracture risk and prevention of adverse effects of alendronate among patients treated with alendronate in Palestine.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine
    Asma Radwan
    Naser Shraim
    Josephean Elaraj
    Anwar Hamad
    Dana Fatayer
    Bayan Jarar
    Ayoub Johar
    Areen Zriqah
    [J]. BMC Women's Health, 22
  • [2] ALENDRONATE 70 THERAPY IN ELDERLY WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: THE PROBLEM OF COMPLIANCE
    Sewerynek, Ewa
    Stuss, Michal
    Malkowski, Bogdan
    Karzewnik, Ewa
    Stepien-Klos, Wioletta
    Tabaszewska, Maria
    Lasota, Marek
    Krupinska, Grazyna
    Gladalska, Anna
    Horst-Sikorska, Wanda
    [J]. OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 179 - 179
  • [3] Compliance with alendronate 10 treatment in elderly women with postmenopausal osteoporosis
    Sewerynek, Ewa
    Dabrowska, Katarzyna
    Skowronska-Jozwiak, Elibieta
    Zygmunt, Arkadiusz
    Lewinski, Andrzej
    [J]. ENDOKRYNOLOGIA POLSKA, 2009, 60 (02) : 76 - 81
  • [4] Satisfaction, preference and compliance with alendronate and risedronate in postmenopausal women with osteoporosis
    Pérez, LI
    Sanidefonso, MM
    Paleo, EE
    [J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S42 - S42
  • [5] Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women
    Ringe, J. D.
    Christodoulakos, G. E.
    Mellstroem, D.
    Petto, H.
    Nickelsen, T.
    Marin, F.
    Pavo, I.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (11) : 2677 - 2687
  • [6] Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
    You, Ruxu
    Liu, Zijie
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [7] Persistence with weekly alendronate therapy among postmenopausal women
    J. C. Lo
    A. R. Pressman
    M. A. Omar
    B. Ettinger
    [J]. Osteoporosis International, 2006, 17 : 922 - 928
  • [8] Persistence with weekly alendronate therapy among postmenopausal women
    Lo, J. C.
    Pressman, A. R.
    Omar, M. A.
    Ettinger, B.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 (06) : 922 - 928
  • [9] Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis
    Curtis, Jeffrey R.
    Arora, Tarun
    Liu, Ye
    Lin, Tzu-Chieh
    Spangler, Leslie
    Brunetti, Vanessa C.
    Stad, Robert Kees
    Mcdermott, Michele
    Bradbury, Brian D.
    Kim, Min
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 (07) : 826 - 834
  • [10] COMPARISON OF PREFERENCE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS BETWEEN THERAPY WITH DENOSUMAB AND/OR ALENDRONATE
    Solakov, Panayot
    Kuzmanova, Stefka
    [J]. OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S274 - S274